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Summary 
T cells are extensively trained on ‘self’ in the thymus and then move to the periphery, where 
they seek out and destroy infections and regulate immune response to self-antigens. T cell re-
ceptors (TCR) on T cells’ surface recognize T cell epitopes, short linear strings of amino acids 
presented by antigen-presenting cells. Some of these epitopes activate T effectors, while others 
activate regulatory T cells. It was recently discovered that T cell epitopes that are highly con-
served on their TCR face with human genome sequences are often associated with T cells that 
regulate immune response. These TCR-cross-conserved or ‘redundant epitopes’ are more 
common in proteins found in pathogens that have co-evolved with humans than in other non-
commensal pathogens. Epitope redundancy might be the link between pathogens and autoim-
mune disease. This article reviews recently published data and addresses epitope redundancy, 
the “elephant in the room” for vaccine developers and T cell immunologists.  
Keywords 
T cell epitope, Regulatory T cell, Cross-conservation, T cell receptor, TCR, TCR Degeneracy, 
Molecular mimicry, Autoimmune disease, Immunoinformatics, Guillain Barre Syndrome, Narco-
lepsy, Multiple Sclerosis, Vaccine, Off Target Effects, HIV, HCV, H7N9, Influenza Vaccine, Can-
cer Vaccine, Virus, Bacteria, Parasite. 
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 Introduction  
Like samurai warriors, T cells undergo extensive training on self-antigens in the thymus before 
venturing into the periphery to fight infections. Some T cells use their T cell receptors (TCR) to 
search and counter  pathogens, while others find T cell epitopes that seem to be more likely to 
trigger regulation or suppression of immune response (Figure 1). However, by definition, naïve 
T cells that escape deletion in the thymus to war against pathogens in the periphery have T cell 
receptors that are trained on ‘self’ T cell epitopes. Some of the T cells become regulatory T cells 
(Tregs), while others become effector T cells (Teff). 
How T cells develop to perform the function of ‘killer’ T cells, despite being trained on self-
epitopes in the thymus, is one of the greatest mysteries of immunology. Deregulation or abnor-
mal activation of these functions leads to immune intolerance, such as autoimmune diseases or 
allergy. While vaccines are safe for the large majority of people and generate herd immunity that 
protects vulnerable persons who cannot be immunized, some vaccines have been associated 
with the induction of autoimmune responses, as observed in the recent cases of narcolepsy that 
were associated with H1N1 influenza vaccination [1].  
Computer analysis of T cell epitopes is now uncovering patterns of amino acids that may be as-
sociated with each of these T cell types. Taking advantage of this system, pathogens have 
found ways to circumvent immune detection, reducing the likelihood that they will be eliminated 
by our humoral and cellular immune system. They do this by removing Teff epitopes (immune 
escape) and, as has been discovered recently, by adopting epitopes that look like human 
epitopes (immune camouflage). There is much that we can learn from defining and understand-
ing these redundant epitopes - such as T cell epitopes found in pathogens - about ourselves 
and our microbial enemies.  
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The development of safer vaccines might be dependent on the identification of which T cell 
epitopes present in the vaccine – and by extension, the pathogen – triggers this reaction against 
self. Computer algorithms for predicting and analyzing T cell epitopes have made it possible to 
discern common patterns that are important for regulating immune responses to self. They may 
be applied not only to design better vaccines but may also contribute to development of new 
treatments for autoimmune diseases. This article reviews the concept of epitope redundancy, 
describes the immunoinformatics tools to identify epitope redundancy, and discusses the rele-
vance of this approach to design better vaccines and understand pathogen-related autoimmune 
diseases.  
TCR specificity in T cell development 
As a result of the selection steps in the thymus, conventional T cells and natural regulatory T 
cells (nTreg) emerge with an intermediate level of self-reactivity, one that exceeds the level 
leading to clonal deletion and falls below the level for negative selection (Figure 2). Little is 
known about T cell epitope specificity of nTregs. Some studies support a “buddy” hypothesis 
that TCRs of conventional and nTreg cells share the same specificity, which serves to prevent 
autoimmunity [2]. Consistent with this concept, the TCR repertoire of thymic-derived effector T 
(Teff) cells and Tregs has been shown to overlap to some degree [3]. Other TCR repertoire 
studies have not shown overlapping repertoires [4-6]. Further studies, focusing on the exact 
specificities of conventional Teff cells versus nTregs, are clearly needed, so as to better under-
stand the implications of overlapping TCR repertoires. Based on current understanding of the 
maturation of T cell subsets, there appears to be a swords-edge balance between protective 
immune response to pathogens and regulation of autoimmunity in the periphery. 
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TCR degeneracy, Epitope Redundancy, Mimicry and Camouflage 
T cells are activated when T cell epitopes, short linear strings of amino acids, are presented at 
surface of APCs in the context of human leukocyte antigen (HLA) molecules. The peptide-HLA 
complex presents a unique surface that is recognized by the TCR. The topic of T cell epitope 
cross-reactivity, believed to be due to TCR degeneracy or lack of fine specificity, is a concept 
that is familiar to infectious disease and autoimmune disease researchers. Conservation be-
tween T cell epitopes from different strains of a given pathogen is well known (e.g., influenza [7] 
and Dengue [8]).  
In the realm of autoimmunity, similarity between self and pathogen has also been called mo-
lecular mimicry [9]; however this terminology does not allow for differentiation between different 
types of mimicry - structural (as in cross-reactive B cell epitopes), or mechanism-related (as in 
Epstein - Barr virus (EBV)’s adoption of IL-10 as a mediator of immune regulation [10]). In this 
article, we will specifically focus on T cell epitope redundancy, as defined below, which is one of 
the direct results of the TCR training on self in the thymus [11] and education of these T cells in 
the periphery [12]. Our focus on cross-reactivity of T cell epitopes is enabled by the develop-
ment of accurate computational tools for the identification of these epitopes [13,14] and enliv-
ened by reports associating autoimmune diseases to exposure to pathogens, such as the recent 
report linking narcolepsy to influenza exposure or vaccination [15].  
Cross-reactivity occurs because TCRs are somewhat ‘promiscuous’ in that they can recognize 
remarkably similar (but not necessarily identical) epitopes that are defined by binding to the 
same HLA and presentation of similar TCR-facing residues to the TCR. Complex relationships 
between T cell epitopes have been described by Welsh and Selin [16], in which different 
epitopes (different in sequence) may be recognized by the same T cell. They have called this 
cross-conservation between pathogens heterologous immunity, as previous exposure to the 
conserved epitope can pre-define immune response to a novel pathogen. We define ‘redundant’ 
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epitopes as non-self linear sequences that bind to the same HLA and may be recognized by the 
same TCR as a self-epitope despite differences at HLA binding positions. Human commensal 
pathogens that have established a pattern of ‘hit and stay’ (such as herpes simplex virus) have 
more redundant sequences than pathogens that ‘hit and run’ (such as Ebola and Marburg) 
[17,18]. To what degree this redundancy may contribute to autoimmunity, is as yet unknown 
[19].  
Heterologous immunity [ 20 - 24 ] may also involve TCR recognition of similar HLA-binding 
epitopes that exhibit variability at TCR-facing positions. However, existing methods for the iden-
tification of heterologous epitopes, in which the epitopes may not be similar in sequence but 
trigger cross-reactive T cell responses, are cumbersome. Redundant epitopes comprise linear 
sequences that are identifiable using computational methods [13]. These computational meth-
ods enable large-scale comparisons to peptides across genomes (the human genome, a cancer 
genome, the intestinal microbiome, viral pathogens, and parasite genomes, to name just a few). 
A limitation of the computational approach at this time is the ability to identify cross-reactive 
TCR specificities, such as those found in heterologous immunity that are defined only by identi-
cal TCR-face sequence. Thus, unlike the category of cross-reactive epitopes that may be de-
fined by intensive studies of heterologous immunity [25], T cell epitope redundancy is defined by 
the ability to examine it using in silico methods. Once the epitopes are defined, methods such 
as TCR clonotyping [26], high-resolution tetramer staining [27,28], and x-ray crystal structural 
determination may help to further elucidate the nature of the TCR-cross-reactive immune re-
sponses. 
We have postulated that epitope redundancy might enable pathogens to camouflage them-
selves from immune response. Other means of immune escape by pathogens have been well 
described [29]. For example, Gram-negative bacteria can escape innate immunity through struc-
tural modifications of their PAMPs, thus escaping recognition by phagocytes [30]. Plasmodium 
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falciparum, the parasite responsible for malaria, can also escape the human immune system by 
mutually exclusive gene expression of the var gene family, leading to antigenic variation [31]. 
Survival within macrophages may be an immune evasion and persistence strategy of C. glabra-
ta [32]. Viruses have also developed sophisticated means of escaping immune response. They 
can escape the first round of innate immunity by impairing monocyte differentiation into func-
tional DCs [33,34] or develop “shape change” strategies, such as impairing non-self RNA 
recognition by replicating the self cap structures [35]. EBV produces a regulatory cytokine that is 
nearly indistinguishable from human IL-10 [36,37]. In response to attack by T cells, pathogens 
such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have been demon-
strated to avoid T-cell mediated response by the deletion of Teff epitopes [38-40].  
Adding to this repertoire of escape mechanisms, we recently described “self-like” or redundant 
epitopes in certain viruses that exhibit on the TCR face patterns that are conserved with human 
Treg epitope sequences, potentially reducing immune response against the pathogen. We pro-
posed a novel means of immune escape - immune camouflage – that can be discovered using 
immunoinformatics tools that compare T cell epitopes [17]. Further evidence is emerging that 
HIV [41], HCV [42], EBV, HSV, and avian influenza (H7N9) [43] have built themselves a very 
successful niche using bits and pieces of the human genome, which allow them to create an 
immune signature that is indistinguishable from self.  
The impact of Immune camouflage through epitope redundancy in immune responses to patho-
gens may be difficult to discern at the population level, since the net effect of these influences 
may vary in different individuals due to previous exposures, vaccinations, and the HLA-
restriction of cross-reactive immune responses. The identification of redundant epitopes that are 
restricted by multiple HLA, as described in the next section, has enabled our group to evaluate 
these epitopes in vitro and define patterns that may be associated with regulatory or auto-
reactive immune response.  
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Redundancy and regulation of T cell response 
It should be noted that cross-conservation of T cell epitopes from pathogens and autoantigens, 
and studies that show that these epitopes can be either immune-regulatory and/or immunostim-
ulatory, is not a new discovery. For example, heat shock proteins have been the focus of in-
tense research, as they are conserved in bacterial species and humans. Van Herwijnen et al. 
found a mycobacterial (Mtb) HSP70 peptide (B29) that is highly conserved with human to be an 
immunodominant peptide in BALB/c mice [44]. They adoptively transferred the Mtb B29-specific 
Tregs and were able to show that these mycobacterial epitope-specific Tregs suppressed ongo-
ing experimentally induced arthritis in mice. In a separate study, peptides H161 and H167, de-
rived from the most conserved region of HSP70 (both among species and among human 
HSP70 variants), showed strong recognition by PBMCs of healthy humans; T cell proliferation, 
gamma-interferon production and IL-10 secretion were reported [45]. More recently, peptides 
derived from HSP “BiP” were shown to include T cell proliferation, IL-10 expression, and to re-
duce inflammation in a murine model [46]. In a separate study, stress-induced presentation of 
HSP-derived peptides in mouse APC resulted in activation of CD4+ hybridoma T cells specific 
for the identified peptide [47]. The current explanation for this observation is that stress-induced 
augmented expression of inducible HSP70 leads to enhanced presentation of HSP70 peptides 
on MHC class II, leading to recognition by HSP70-specific T cells, which may subsequently 
dampen inflammation [48]. It is not clear whether these HSP-specific T cells are iTreg or nTreg, 
or even T eff, and how they evolve to adapt a particular phenotype. We have examined these 
epitopes for epitope redundancy, and did find that the epitopes are not only promiscuous, but 
they are also highly conserved (across HSP proteins) and that many HSP peptides are found in 
the thymic and lymph ‘peptidomes’ [49,50,51]. 
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Epitope Mapping using Computational Tools 
The process of identifying which pathogen sequences trigger T effector immune responses and 
which trigger regulatory T cell responses may have been simplified by the development of 
epitope-mapping tools. Most T cell epitope mapping tools evaluate the amino acid sequence of 
each input 9-mer peptide (derived from the set of overlapping 9-mer sequences in any protein 
antigen) to a set of binding coefficients that define the propensity of the sequence to bind to 
HLA. On an overall scale, proteins carrying more putative epitopes would expected to be more 
immunogenic while proteins carrying fewer putative epitopes would tend to be less immunogen-
ic [14]. On a local scale, T-cell epitopes (class II-restricted in particular) are not randomly dis-
tributed throughout protein sequences but instead tend to “cluster” in specific regions, and are 
known as promiscuous T cell epitopes [52]. Promiscuous class II restricted T-cell epitope “clus-
ters” can range from 9 to roughly 25 amino acids in length and, considering their affinity to mul-
tiple alleles and across multiple binding registers, can contain anywhere from 4 to 40 binding 
motifs. Many of the most reactive T-cell epitope clusters present a feature we have described as 
an “EpiBar” (Epitope Bar). An EpiBar is a single 9-mer frame containing binding motifs for at 
least four different HLA alleles (Figure 3). In retrospective evaluations of published promiscuous 
epitopes, we have found this pattern to be a signature feature of highly immunogenic, promis-
cuous class II epitopes [53,54].  
Some promiscuous epitopes that have this feature and are highly redundant (either found in 
very prevalent proteins, or highly cross-conserved with the human genome) have been shown 
to trigger Tregs to respond and expand. This discovery has been true for epitopes discovered 
by our group (IgG T cell epitopes known as Tregitopes [12], HCV [42], H7N9 [43]) as well as for 
Treg epitopes discovered by other groups such as Edratide [55] and epitopes found in heat 
shock proteins: HSP60 [56,57,58], HSP 70 [48] and BiP [46].  
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Improving computational tools to identify epitope redundancy 
To investigate further this newly discovered TCR-facing epitope redundancy on a very large 
scale, we built an algorithm called JanusMatrix that can identify peptides with similar MHC-
binding propensities that are TCR-face homologous, in any genome, as compared to a refer-
ence epitope [13]. After the binding prediction analysis described above has been run on an an-
tigen, JanusMatrix compares the 9-mer’s TCR-facing residues to the proteins of the human ge-
nome and the human microbiome. Significant differences between the degree of cross reactivity 
with protein databases of human genome, human microbiome, and human pathogen sequences 
when comparing known T effector and T regulatory epitopes are identified by ratios [13]. Ja-
nusMatrix “Homology” score is calculated by determining the average depth of coverage in the 
target database for each epitope identified in the source sequence. Homology to non-binding 
peptides is assumed to be irrelevant. 
JanusMatrix is now used by our group and our collaborators to identify significant cross-
conservation with proteins contained within the human genome and the human microbiome. We 
found that immune response to T cell epitopes was inversely correlated with their degree of 
cross-reactivity with the human genome in a subsequent study of H7N9 peptides [43]. Examin-
ing more than 4,000 published human T cell epitopes (from the Immune Epitope Database, 
IEDB, http://www.iedb.org/), we recently determined that the JanusMatrix “homology” score is 
significantly higher (p<0.0001) for T cell epitopes shown to induce regulatory cytokine (IL-10) 
response (N=3,780 epitopes), and significantly lower (p<0.01) for T cell epitopes shown to in-
duce effector cytokine (IL-4) response (N=1,433 epitopes) [14]. Thus large-scale analysis of 
published T cell epitopes in public databases has provided additional confirmation for the hy-
pothesis that epitope-redundancy deviate the phenotype of T cell-mediated immune responses. 
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From redundant epitopes to Treg epitopes  
Using JanusMatrix, we identified human-like T cell epitopes in the genomes of viruses and bac-
teria. Analyzing pathogens that co-evolved with humans (e.g. EBV, CMV, HIV), we identified a 
disproportionately large number of linear epitopes that possess TCR-facing amino acid se-
quences that are highly conserved with self [17]. In the following paragraphs, we provide a 
summary of Treg epitopes that were identified using JanusMatrix, in H7N9, HCV, and HIV.   
 Treg epitopes in H7N9 influenza 
Avian-origin H7N9 influenza is a novel influenza A virus that emerged in humans in China in 
2013. Using JanusMatrix, we identified several H7N9 T cell epitopes with TCR-facing residues 
identical to those of multiple epitopes from human proteins [59]. These H7N9 human-like T cell 
epitopes possess low immunogenicity; in PBMCs derived from healthy donors, human Teff re-
sponses to individual H7N9 peptides was inversely correlated with the degree of the peptide’s 
resemblance to self [43]. The human-like H7N9 version of an immunodominant hemagglutinin T 
cell epitope suppressed IFN-gamma responses when co-administered with peptides having less 
cross-reactivity with the human genome. T cells that respond to this epitope demonstrated a 
Treg phenotype [43]. In further as yet unpublished work, we have demonstrated that the Treg-
activating epitopes may contribute to lower antibody responses in humanized mice, and modifi-
cation of these epitopes may improve H7N9 vaccine efficacy.  
 HCV Treg epitopes 
Using JanusMatrix, we discovered a promiscuous class II epitope in HCV that is conserved with 
hundreds of human homologs. The epitope induces CD4+CD25+FoxP3+ Treg proliferation and 
function in peripheral blood leukocyte cultures from an HLA-diverse cohort of HCV-infected pa-
tients, but not in patients who spontaneously cleared HCV nor in non-infected individuals [42]. 
Human homologs of the HCV epitope stimulate Tregs in both HCV- and non-infected people, 
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suggesting that tolerance of this particular protein is promoted by activation of Tregs that recog-
nize a common TCR-face. It is well known that HCV epitopes mutate over the course of infec-
tion to decrease MHC binding. This has been well-defined for CTL epitopes, but is less well de-
fined for CD4+ T cell epitopes [60-62]. However, in the case of the HCV epitope described by 
Losikoff et al. [42], the HCV genomic sequences appears to contain the same TCR-facing resi-
dues as highly prevalent autologous T cell epitopes, so as to acquire the potential to drive Treg 
responses in an HLA-diverse population.  
 HIV Treg epitopes 
HIV also exhibits curious patterns of cross-reactivity by JanusMatrix analysis. In searching HIV 
envelope sequences for cross-conservation with the human genome, we recently uncovered a 
high frequency of human MHC molecule sequences that share a TCR-face with a highly con-
served human epitope in the envelope protein (orange highlight, Figure 4). This protein is pre-
sent on the cell surface of nearly every living cell, and the conserved epitope is a highly con-
served motif, despite allelic variation. An IEDB search shows a closely related epitope has been 
described as capable of stimulating T cell proliferation [63] (the phenotype of the proliferating 
cells was not defined). If these CD4+ T cells are regulatory in nature, activation of the T cells by 
the HIV homolog epitope could promote HIV expansion [64], which may promote HIV viral per-
sistence and increase HIV ‘fitness’, instead.  
These three case studies are consistent with our previously published observation that that ‘hit 
and stay’ viruses like HCV and HIV escape protective immune responses by cross-reacting with 
Tregs [17] and suggests that Treg-activating HCV and HIV sequences may affect HIV and HCV 
vaccine efficacy.  
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 Patterns may be common to Treg epitopes 
In our retrospective evaluations of the computational signature of these promiscuous, Treg-
inducing epitopes, we find several common characteristics that may be useful for future studies. 
First, as suggested above, the T cell epitopes that induce Treg responses tend to be promiscu-
ous epitopes (presented by multiple class II HLA DR alleles), and second, they tend to be found 
in extremely prevalent proteins (such as Immunoglobulin G for Tregitopes and Edratide 
(hCDR1), and heat shock proteins such as HSP 60 (Diapep277, [57]) and HSP 70 [65]. A third 
feature that is common to such epitopes, when found in pathogens, is that their sequence of 
amino acids that face the TCR face may be identical, or redundant, with many human genome 
sequences that are predicted to bind to the same MHC alleles [17]. This suggests that the prev-
alence of peptides (or the frequency with which circulating T cells may encounter peptides) that 
bind to the same MHC and present the same TCR face to the T cell may be important in terms 
of determining the phenotype of the immune responses.  
Redundant epitopes in autoimmune diseases 
Epitope redundancy may also cause the immune response to go awry, where cross-reactivity 
between pathogen and self triggers effector T cell response against self. Due to TCR cross-
recognition between self and pathogen, exposure to a pathogen may trigger anti-self responses, 
leading to the initiation of an auto-immune condition. A number of examples have been pub-
lished, such as conservation between certain EBV and autologous epitopes in nerve-associated 
proteins, potentially contributing to the development of Multiple Sclerosis (MS) [66] (Figure 5). 
Vaccination has also been reported to be associated with immune diseases [15,67,68]. Genes 
involved in TCR recognition of epitopes such as HLA-DRB1, CD4 and INF-gamma or TGFbeta1 
have been involved in autoimmune diseases known to be associated with vaccination [69]. In 
the next section, we will focus on recent advances on selected autoimmune diseases that are 
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believed to be related to infection with pathogens, and explore whether epitope redundancy 
could explain many of these autoimmune-infectious disease linkages.  
 Guillain-Barré Syndrome 
Guillain-Barré syndrome (GBS) is the main cause of acute flaccid paralysis, characterized by a 
weakness in muscle contraction. In about 60% of the cases, an upper respiratory or gastrointes-
tinal infection precedes the onset of the disease. Among the pathogens that trigger GBS, Cam-
pylobacter jejuni (C. jejuni) is the most frequent (in 13% to 39% of cases), followed by cytomeg-
alovirus (5% to 22%), EBV (1% to 13%), and Mycoplasma pneumoniae (5%) [70]. One of the 
most documented mechanisms for GBS is the presence of anti-gangliosides antibodies (anti-
GM1 and anti-GD1), induced by similarity of these self-proteins with lipo-oligosaccharides pre-
sent on C. jejuni’s LPS [71]. There is also evidence of an association between influenza virus 
and GBS. In 1976 and 2009 in the US, seasonal influenza strains were of swine origin and an 
increased relative risk of developing GBS was observed in both cases, whether the vaccine was 
adjuvanted or not [72,73]. Although these results were not confirmed in Europe [74], several 
studies have established a link between GBS and infection by the 2009 pH1N1 [75,76].  
How the swine influenza virus and the associated vaccines may have triggered GBS is not cur-
rently known. Although anti-ganglioside antibodies can recognize the influenza virus (probably 
due to glycosylation), no such antibodies were found in sera of vaccinated patients [77]. Alt-
hough no studies have identified specific T cell epitopes involved, it is clear that their formation 
is T cell-dependent. Several populations of T-helper cells have been identified in cases of C. Je-
juni-induced GBS [78], and immunoglobulin class-switching has been observed in transgenic 
mice that lack complex ganglioside when immunized with C. Jejuni LPS [79]. Evaluation of po-
tential cross-reactivity between GBS-associated antigens in pathogens and self is both feasible 
and actionable using JanusMatrix. 
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 Narcolepsy 
Narcolepsy is a neurological disorder characterized by a selective loss of hypocretin-secreting 
neurons that results in excessive daytime sleepiness [80]. Strong genetic associations with se-
lected HLA alleles in narcolepsy provides support for an autoimmune basis of hypocretin-
secreting neuron loss. Narcolepsy occurs almost exclusively in patients whose HLA is 
DQA1*01:02 and DQB1*06:02 [81,82]. Strong correlations between the onset of narcolepsy with 
Streptococcus pyogenes [83] and influenza A virus infections have been reported, with epitope 
redundancy suspected to play a major role in triggering the autoimmune reaction. A 6-9 fold in-
crease in the risk of developing narcolepsy was observed following 2009-2010 H1N1 influenza 
pandemics in Europe [84,85] and China [86]. In these regions, the onset of narcolepsy was ob-
served following vaccination with Pandemrix, an adjuvanted pH1N1 vaccine. A recent report has 
identified the presence of autoantibodies against ganglioside GM3 in Pandemrix-vaccinated 
children who developed narcolepsy with cataplexy [87], providing additional support for the the-
ory that influenza-associated narcolepsy is autoimmune, and suggesting an underlying mecha-
nism similar to GBS. Markers of inflammation (interferon gamma, CCL11, IL12) identified by 
Luminex assay have been associated with onset of narcolepsy [88]. 
In addition, a peptide from the surface-exposed region of influenza nucleoprotein A shared pro-
tein residues with a fragment of the extracellular domain of hypocretin receptor 2 in the host.  
Antibodies against these epitopes were present in the sera of individuals that previously re-
ceived the Pandemrix vaccine [15], suggesting that the nucleoprotein A epitope is a redundant 
epitope.  The presence of the adjuvant may have served as a catalyst to establish the autoim-
munity in this particular case. The extent to which the relevant epitope is recognized by patients 
who do not have narcolepsy remains to be determined.  
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 Multiple sclerosis 
Multiple sclerosis (MS) is the most common autoimmune disease, affecting more than 2 million 
people over the world. Demyelination of axons in the central nervous system contributes to the 
neurological disability associated with MS. Th1 and Th17 effector cells have been shown to play 
a major role in the pathogenesis of the disease [89], along with a deficit in Treg cells [90,91]. Vi-
ral or bacterial infections [92,93], commensal microbiota [94] have been associated to MS. 
Cross-conserved or redundant T cell epitopes may be involved in MS pathogenesis [95]. For 
example, a number of stimulatory, cross-reactive peptide sequences from environmental and 
human antigens were found in MS patient-derived anti-myelin TCR [96]. Furthermore, a peptide 
from H. influenzae mimicking a PLP-peptide has been shown to induce CNS disease in a 
mouse model [97]. 
 Autoimmune Disease and the Gut Microbiome 
Links between bacterial infections and autoimmune diseases of the gut have been found 
[98,99]. However, the complexity of the human microbiome may make it difficult to deconvolute 
the many cross-reactive peptides that could be driving this link. Associations between specific 
gut microbes and disease [100] may make it possible to narrow down the possibilities, although 
it seems unlikely that a single gut microbe will be the culprit.  
In conclusion, the impact of epitope redundancy on autoimmunity and infectious diseases may 
be difficult to decipher, since many factors can influence the outcome of infection and immune 
response. Focusing only on the T cell epitope component of the complex interaction between 
host and pathogen, T cell-related determinants of immune response include the breadth of T 
cell epitopes in the pathogen that can be presented to the immune system, and the individual 
HLA molecules that present these epitopes to the host. In addition, differences in immune re-
sponses to specific epitopes may be defined in advance due to previous exposure to the same 
pathogen (memory T cell response) and/or due to exposure to other pathogens that have simi-
D
ow
nl
oa
de
d 
by
 [D
r A
nn
e D
e G
ro
ot]
 at
 07
:27
 24
 N
ov
em
be
r 2
01
5 
lar, cross-reactive epitopes (heterologous immunity). Rather than view these factors as impedi-
ments in the search for linkages between infectious diseases, autoimmunity, and tolerance, we 
view them as new frontiers that can be explored, applying recently developed computational 
tools such as JanusMatrix and T cell phenotyping techniques.  
Expert Commentary 
The development of new immunoinformatics tools have allowed to better define and understand 
the concept of T cell epitope redundancy between self and pathogens. Not only is epitope-
redundancy relevant to host-pathogen immune responses, as it is involved in immune camou-
flage, but it is also relevant to autoimmunity. One of the major challenges to understanding 
mechanisms of immune tolerance and its evil twin, autoimmunity, is to identify the T cell 
epitopes that are recognized by regulatory and effector (inflammatory) T cell populations. Dis-
secting proteins for these linear determinants of T cell activation is essential to designing thera-
pies that will reverse the course of autoimmune diseases and explain long-established linkages 
between autoimmunity and infections. Tools for pathogen-TCR-facing-self-wise analysis are 
now available, making it possible to investigate thse important topics. Further studies are nec-
essary to answer these two important questions: (1) do highly TCR cross-conserved epitopes 
play a key role in tolerance to self; and (2) if epitope redundancy is also relevant to T effector 
epitopes, are epitopes with lower TCR-face cross-conservation associated with post-infection 
autoimmune diseases, such as Narcolepsy and Guillain-Barré syndrome? These are truly fun-
damental questions that are directly relevant to improving vaccines and safeguarding human 
health.  
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Five-year view 
Biomaterial scientists have been adopting lessons learned from pathogens to evade immune 
responses to their products for decades. Can vaccinologists and immunologists, rheumatolo-
gists and maybe also biologics developers learn about the immunopathogenesis of disease 
through explorations of epitope redundancy? To be more precise, perhaps we should learn from 
viruses, bacteria and parasites, by examining which host epitopes they choose to imitate. Why 
do they camouflage themselves with one epitope (sometimes multiple pathogens use the same 
'self' epitope) and not the other? Do those [human] epitopes play a key role in the regulation of 
human immune response? Putting those special epitopes into biologics, may reduce immune 
responses to the drugs, improving patient outcomes. And taking them out of vaccines, may re-
sult in better vaccines. What has proven to be a weakness in host defense, may be the hope 
that emerges, leading to solutions for unmet medical needs. 
It is time that we explore host-pathogen cross-reactivity at the molecular level, expanding the 
application of immunoinformatics analysis to new pathogens, and to pursue interdisciplinary 
studies of the immunopathogenesis of autoimmune disease and tolerance, with the goal of un-
derstanding the accelerating epidemic of autoimmune disease, and improving vaccine efficacy 
and global health for the 21st century.  
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Key issues 
 T cell epitope cross-conservation, or ‘epitope redundancy’, is a consequence feature of 
TCR training on self antigens in the thymus.  
 Epitope redundancy can be uncovered using computational tools that define epitopes, 
and new tools that allow exploration of TCR-conserved, similar MHC-binding epitopes in 
large sets of peptides (such as the human genome).  
 Numerous studies point to epitope redundancy as a contributor to the development of 
auto-immune disease.  
 New studies are revealing epitope-redundancy as a trigger for tolerance, potentially ex-
plaining the immunomodulatory effect of certain epitopes derived from Heat Shock Pro-
teins, and other as-yet unexplained immunological observations.  
 Applying computational tools to the human genome, to human pathogens, and to the 
human microbiome may uncover new relationships between infectious diseases, auto-
immunity, and tolerance.  
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Figures 
Figure 1. Network of T-cell activation by pathogen epitope 
 
Pathogens are taken by APCs which will present epitopes on their MHC molecules to initiate the 
activation of T cells. Trained in the thymus, T cells can recognize epitopes that are conserved 
on the TCR face between pathogens and autologous (self) proteins, resulting in the activation of 
potentially regulatory pathways (A). Some of these epitopes can also be unique to this patho-
gen, activating T cells that engage the immune response (B). This response may be limited due 
to lack of previous exposure. Pathogen epitopes can also be conserved in the human microbi-
ome (C). The subsequent response can be either regulatory or effector, depending on the expo-
sure.  
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Figure 2. Induction of the TCR repertoire 
 
In the thymus, CD4+ T cells are exposed to self-antigens. TCR interaction with MHC II/self anti-
gen complexes will determine the fate of these T-cells. Those that express a TCR that binds 
with a strong interaction with self will be removed by apoptosis (negative selection), as well as 
those with no interaction with MHC II/antigen complex (death by neglect). T cells with the 
weakest interaction with self-antigens will become conventional T cells (Tconv). Natural regula-
tory T cell (nTreg) arise from a population that interact with self moderately and express FoxP3. 
A population of T cells that interact more strongly with self but lack FoxP3 expression is called 
potential Treg. Conversely, a population of Tconv with a stronger affinity for self will have the 
potential to express FoxP3, thus they are called unstable/Treg-like Tconv. These cells are 
likely to become induced Tregs (iTreg). 
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Figure 3. T cell epitope mapping and immunogenicity scoring 
 
Representation of a Typical EpiBar for the Tetanus toxin peptide AA 1234-1248. Z score indi-
cates potential of a 9-mer frame to bind to a given HLA allele. Scores ≥ 1.64 are considered 
"hits" because they fall in the 95th percentile of binding likelihood, following a normal distribution 
(intermediate blue). Peptides with scores in the 99th percentile are even more likely to bind to 
the given allele, and are shaded dark blue.  Scores ranked in the 90th percentile (shown but not 
highlighted) are considered elevated; all other scores are masked for simplicity. 9-mer frames 
containing four or more alleles scoring above 1.64 are referred to colloquially as an “EpiBars” 
and are highlighted in yellow (see frame 1237: YKKMEAVKL). This band-like pattern is charac-
teristic of promiscuous epitopes. The Cluster Score represents the deviation in aggregate 
epitope content relative to the random expectation for a peptide of similar length; Cluster Scores 
above +10 are considered significant. 
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Figure 4. JanusMatrix analysis of HIV-1 Env 
 
Epitope network depicting the degree of similarity between the Treg-inducing 'human-like' HIV-1 
Env peptide (green diamond). From this peptide, three 9-mer frames were predicted to bind 
HLA (grey squares). JanusMatrix identified cross-conserved 9-mers in the human genome (dark 
blue triangles), that were linked to their source human proteins (circles). Some of these human 
sequences were found in multiple human source proteins (orange highlights), indicating that this 
epitope is highly redundant.    
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Figure 5. Graphic representation of JanusMatrix networks for epitopes identified 
in auto-immune diseases 
 
Epitopes identified in autoantigens involved in various autoimmune diseases were tested in Ja-
nusMatrix: A. Ribonucleoprotein in Mixed Connective Tissue Disease (MTCD) [101]; B. Topoi-
somerase in Systemic Scleroderma [102]; C. NY-ESO-1 in cancer [103]; D. Glutamic acid de-
carboxylase 65 (GAD) in type 1 diabetes [103]; E. Desmoglein 3 in Pemphigus Vulgaris [104]. 
The limited networks found for each of these auto-antigens indicates a high likelihood of in-
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flammatory response. Green diamonds represent the original peptide analyzed in JanusMatrix; 
Grey squares are the 9-mer frames predicted to bind a certain HLA; Dark blue triangles are 9-
mers found in the human genome that shares TCR contact residues; Blue circles represent the 
source protein of these human 9-mer frames.
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